

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A process to induce an effector cell mediated immune response against tumor cells in a cancer patient, said method comprising administering, to a cancer patient, a purified, biologically generated virus or virus-like particle with a cellular membrane from a host cell, said membrane comprising an MHC molecule that presents one or more tumor specific antigens, and a co-stimulatory molecule, wherein said administering is of an amount effective to induce an effector cell mediated immune response against tumor cells in said patient.

2. (Previously presented) The process of claim 1 wherein said immune response is mediated by T cells.

3. (Previously presented) The process of claim 1 wherein said biologically generated particles are released from homologous tumor cells from the patient.

4. (Previously presented) The process of claim 1 wherein said biologically generated particles are released from matched major histocompatibility complex containing tumor cells.

5. (Previously presented) The process of claim 1 wherein said biologically generated particles are released from non-homologous tumor cell lines containing one or more matched human leukocyte antigens.

6. (Original) The process of claim 1 wherein said particles are generated as virus-like-particles.

7. (Original) The process of claim 1 wherein said particles are generated as inactivated intact virus particles.

8. (Currently amended) A process for treating a cancer patient to induce in said patient an effector cell immune response against the cancerous cells, comprising administering to a cancer patient ~~tumor-derived~~ biologically generated particles that have been modified to mimic cells capable of presenting antigens to a mammalian immune system, in an amount effective to induce an immune response against the cancerous cells, whereby in the cancer patient the immune response would reduce the amount of cancerous cells, and wherein said particles mimic dendritic cells.

9-15. (canceled)

16. (Previously presented) The process of claim 1 wherein said immune response reduces the number of tumor cells in said patient and thereby treats cancer in said patient.

17. (Previously presented) The process of claim 1 wherein said host cell expresses one or more tumor specific antigens on the cell's cell membrane and said particle has a membrane that further comprises the one or more antigens.

18. (Previously presented) The process of claim 1 wherein said particle mimics a dendritic cell.

19. (Currently) A process to induce an effector cell mediated immune response against tumor cells in a cancer patient, said method comprising
preparing and purifying a biologically generated virus or virus-like particle with a membrane from a host cell, said membrane comprising
an MHC molecule that presents one or more tumor specific antigens, and
a co-stimulatory molecule; and
administering said particle to a cancer patient in an amount effective to induce an effector cell mediated immune response against tumor cells in said patient.

20. (Previously presented) The process of claim 19 wherein said host cell expresses one or more tumor specific antigens on the cell's cell membrane and said particle has a membrane that further comprises the one or more antigens.

21. (Previously presented) The process of claim 1 wherein said host cell is a non-tumor cell.

22. (Previously presented) The process of claim 19 wherein said host cell is a non-tumor cell.

23. (Previously presented) The process of claim 1 wherein said co-stimulatory molecule is a B7 family molecule.

24. (Previously presented) The process of claim 17 wherein said co-stimulatory molecule is a B7 family molecule.

25. (Previously presented) The process of claim 19 wherein said co-stimulatory molecule is a B7 family molecule.

26. (Previously presented) The process of claim 20 wherein said co-stimulatory molecule is a B7 family molecule.